RxDoctor Payments Data

Jeff Bronstein, MD

Neurology · Los Angeles, CANPI 1114940731

Payments from drug & device makers

$752,561in general payments, 2019–2025

Across 117 payments — averaging $6432.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ultragenyx Pharmaceutical Inc.$320K
  • AstraZeneca$287K
  • AbbVie$103K
  • MDD US Operations, LLC$41K
  • Bayer$2K
  • Pfizer$23
  • plus $11 from 1 others

What the payments were for

  • Consulting fees$14,02589%
  • Travel & lodging$1,2278%
  • Food & beverage$4843%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Ultragenyx Pharmaceutical Inc.51$320,470
AstraZeneca14$287,069
AbbVie29$102,633
MDD US Operations, LLC11$40,760
Bayer10$1,595
Pfizer1$23
Acadia Pharmaceuticals Inc1$11

How this compares

$752,561 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$80,579
Medicare patients
195
Services billed
506

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate174$1,155,136
ApokynApomorphine Hcl11$832,654
RytaryCarbidopa/Levodopa148$166,624
GocovriAmantadine Hcl34$122,001
NourianzIstradefylline31$71,852
OngentysOpicapone54$46,144
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone118$32,057
NeuproRotigotine13$21,900
MyrbetriqMirabegron37$21,196
Rasagiline Mesylate91$20,708
Carbidopa-Levodopa ErCarbidopa/Levodopa202$17,021
Carbidopa-LevodopaCarbidopa/Levodopa285$15,089
Entacapone21$12,719
MotegrityPrucalopride Succinate13$9,473
Modafinil12$7,538

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$11$1,155,136174 claims
MDD US Operations, LLCGocovri$40,760$122,00134 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,996 neurology providers in California.

Other neurology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →